Decision Support Tool to Enhance Germline Genetic Testing for Patients With Prostate Cancer

This clinical trial identifies factors associated with completing genetic testing, aids in the development of a decision support tool, and tests how well the decision support tool works to enhance germline genetic testing in patients with prostate cancer. Germline genetic testing is a guideline-recommended standard of care for many patients with prostate cancer. Completing genetic testing can enable the use of targeted therapies, offers access to novel clinical trials, provides valuable information, and can help identify at risk family members. The decision support tool may educate patients and assist in the decision to engage with germline genetic testing.

NCT Number	NCT07377006
Lead Sponsor	M.D. Anderson Cancer Center
Conditions	Prostate Carcinoma
Enrollment	108 participants
Start Date	2026-10-01
Primary Completion	2030-05-31 (estimated)
Study Completion	2030-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-02-18